摘要
目的探讨肝移植术后乙型肝炎病毒再感染的危险因素和对策。方法对2003年9月到2004年12月间在我院肝脏移植中心施行肝移植术且符合研究标准的130例病例进行前瞻性研究，采用肌注剂型HBIg联合核苷类抗病毒药物联合预防HBV再感染并长期随访，分析HBV再感染的危险因素。结果130例中128例术后血清HBsAg转为阴性并检测到HBsAb，平均随访12．2个月，HBV再感染率为6．3％（8／128例）。结论肝移植术前HBeAg阳性、HBVDNA定量达到或超过10^5eopies／ml、术后1dHBsAg阳性及HBsAb〈200U／L是HBV再感染的危险因素。
Objective To investigate the risk factors of HBV reinfection after liver transplantation and explore countermeasures for their disposal. Methods The clinical data of 130 patients undergoing liver transplantation in our hospital for HBV-related end-stage liver disease from September 2003 to December 2004 were retrospectively analyzed. All the 130 patients received the combined therapy of intramuscular HBIg and oral nucleoside analogs as prophylaxis for HBV reinfection. HBV markers were detected in due time during follow-up period and the risk factors of HBV reinfection were analyzed. Results HBsAg disappeared and HBsAb was detectable in 128 out of the 130 patients. The median follow-up period was 12. 2 months and 8 patients （6. 3%） developed HBV reinfection. Conclusions Serum HBeAg positivity and HBV DNA （ 10^5 copies/ml before and HBsAg positivity and HBsAb concentration less than 200 U/L on the 1st d after operation are risk factors of HBV reinfection.
出处
《中华肝胆外科杂志》
CAS
CSCD
2007年第1期25-27,共3页
Chinese Journal of Hepatobiliary Surgery
基金
本课题受广州市科技计划项目（200523-E0101）、广东省科技项目（2005830501005）、广东省自然科学基金（0400g391）、科技部973计划（2003CB515507）资助
关键词
肝移植
乙型肝炎
再感染
危险因素
Liver transplantation
Hepatitis B
Reinfection
Risk factor
